Back to news

BrainStorm Cell Therapeutics Announces Third Quarter 2026 Financial Results and Provides Corporate Update

PR Newswire•16/11/2026•16:01 ET
0

Key Highlights

  • ➤Phase 3b ENDURANCE preparations advance under an FDA-agreed Special Protocol Assessment
  • ➤Net loss approximately $1.7 million, improving from approximately $2.1 million year over year
  • ➤Cash, cash equivalents, and restricted cash were approximately $0.35 million
  • ➤Peter J. Pitts appointed Executive Chairman and Chief Strategic Regulatory and Policy Officer

Expert Statements

Chaim Lebovits, President and Chief Executive Officer of BrainStorm

“ALS remains a devastating disease with a critical unmet medical need, and patients urgently need new therapeutic options. We continue to advance and complete the preparations necessary to initiate the Phase 3b ENDURANCE study of NurOwn(®) in ALS, supported by an FDA-agreed protocol under a Special Protocol Assessment. During the third quarter, we strengthened our leadership with the appointment of Professor Peter J. Pitts as Executive Chairman and broadened our engagement with regulators, potential commercial partners, and investors. Professor Pitts has joined the Company in an active executive capacity and is helping lead the regulatory, operational, partnership, and capital-markets initiatives surrounding the NurOwn program. His experience as a former senior FDA official brings an additional level of regulatory insight and strategic perspective as we prepare to enter this important next phase, and we remain resolute in our commitment to advancing what we believe will be a valuable new therapeutic option for the ALS community.”

BrainStorm Cell Therapeutics Announces Third Quarter 2026 Financial Results and Provides Corporate Update PR Newswire

NEW YORK, Nov. 16, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the third quarter ended September 30, 2026, and provided a corporate update.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in